EC bill
This article was originally published in The Tan Sheet
Executive Summary
Representative Steven Rothman, D-N.J., et al. introduced H.R. 464, the Compassionate Assistance for Rape Emergencies Act of 2007, on Jan. 12 to require hospitals that receive federal funds through Medicare or Medicaid to provide information on emergency contraceptives and offer such products to female patients being treated following sexual assaults. The bill was referred to the Energy and Commerce and Ways and Means committees...
You may also be interested in...
EC for rape survivors
The Connecticut Senate passes a bill April 25 to require licensed health care facilities to provide sexual assault survivors with emergency contraception upon request. The bill (S.B. 1343) moves to the House for a vote. Separately, the Wisconsin Legislature addresses a similar measure (S.B. 129) in a public hearing April 25. The Wisconsin bill not only provides emergency contraception upon request, but penalizes noncompliant hospitals. Also, Rep. Michael Michaud, D-Maine, et al., introduce a bill (H.R. 2064) April 26 to require the availability of emergency contraceptives to all military health care treatment facilities. The bill is referred to the House Committee on Armed forces. In January, Rep. Steven Rothman, D-N.J., et al., introduced legislation (H.R. 464) requiring hospitals receiving federal funds to provide information on EC as well as the product for women treated for sexual assault at the facility (1"The Tan Sheet" Jan. 29, 2007, In Brief)...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.